NCT06577636 (IDEA_PTSD) is a Phase 2 clinical trial of Propofol anesthesia in PTSD, sponsored by Stanford University.

Who is sponsoring NCT06577636?

NCT06577636 is sponsored by Stanford University.

What drugs are being tested in NCT06577636?

Interventions in NCT06577636: Propofol anesthesia.

What condition does NCT06577636 study?

NCT06577636 studies PTSD, Post-traumatic Stress Disorder.

Is NCT06577636 still recruiting?

NCT06577636 is currently recruiting now. Last updated 21 February 2026.

Last reviewed 2026-02-21 · How we verify

NCT06577636: IDEA_PTSD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Anesthesia-induced Dreaming for Post-traumatic Stress Disorder: a Randomized Controlled Trial

Recruiting now Phase 2 Last updated 21 February 2026

What this trial tests

Phase 2 trial testing Propofol anesthesia in PTSD in 42 participants. Currently enrolling.

Timeline

21 July 2025

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	Stanford University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	42
Start date	21 July 2025
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Propofol anesthesia — full drug profile →

Conditions studied

PTSD — all drugs for PTSD →
Post-traumatic Stress Disorder — all drugs for Post-traumatic Stress Disorder →

Sponsor

Stanford University

Who can join

Adults 18 to 70, any sex, with PTSD or Post-traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Time frame: 1 month post-intervention
The CAPS-5 is a structured interview that is considered the gold standard for assessing post-traumatic stress disorder (PTSD). The CAPS-5 is designed to assess the 20 symptoms of PTSD as defined by the DSM-5, as well as the impact of these symptoms on social and occupational functioning. The CAPS-5 includes 20 items corresponding to the DSM-5 criteria for PTSD. Each item is rated for both frequenc

Sponsor's own description

The goal of this study is to test whether anesthesia-induced dreaming can help alleviate symptoms of PTSD in an (1) open-label trial (Phase I) and (2) double-blind, randomized controlled trial (Phase II) in a non-surgical setting. The investigators predict that inducing and sustaining a dream state prior to emergence from anesthesia will result in reduced symptoms of PTSD. Participants will undergo EEG-guided propofol anesthesia during which they will be either (1) receiving deep sedation leading to loss of responsiveness, designed to elicit dream reports upon emergence (Dream Protocol), and/or (2) light sedation without loss of responsiveness, designed to elicit non-dream experiential reports while responsive (e.g., simple imagery, sounds, thoughts, bodily sensations, hypnagogic-like experiences) (Non-Dream Protocol). The investigators will then investigate whether the deep-sedation Dream Condition is associated with a larger reduction in PTSD symptoms than the light-sedation Non-Dream Condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Propofol anesthesia

Trials testing the same drug.

NCT04307238 — Effects of Different Types of General Anesthesia on Postoperative Pupillary Reactivity · NA · recruiting

Other recruiting trials for PTSD

Currently open trials in the same condition.

NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
NCT07010757 — Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial · NA · recruiting
NCT07372586 — Behavioral Health Collaborative Care Model in an ICU Recovery Clinic · NA · recruiting
NCT07390786 — Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot · NA · recruiting
NCT07469098 — Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events · Phase 2 · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06577636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 21 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06577636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing